The Effectiveness and Safety of Cardiac Shock Wave Therapy in the Treatment of Ischemic Heart Disease with Refractory Angina Pectoris
Vascular Health and Risk Management · 2025
DOI: 10.2147/vhrm.s559424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vascular Health and Risk Management, 2025. Verfasst von Le Duy Thanh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Heart Institute, 108 Military Central Hospital, Hanoi, Vietnam. Hauptthemen laut MEDLINE: Angina Pectoris, Myocardial Ischemia, Extracorporeal Shockwave Therapy. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
This study investigated the efficacy and safety profile of cardiac shock wave therapy (CSWT) in the treatment of ischemic heart disease (IHD) with refractory angina pectoris.
Methods
A single-arm, pre-post prospective cohort study was conducted on 65 patients with IHD and refractory angina pectoris who were treated at the Department of Cardiology, 108 Military Central Hospital, between March 2015 and March 2021. The participants were prospectively monitored over a 6-month follow-up period.
Results
Significant improvements were observed in angina symptoms, 6-minute walk test performance, Canadian Cardiovascular Society (CCS) angina classification, and New York Heart Association (NYHA) functional class. N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels decreased from 942.75 pg/mL to 410.45 pg/mL. Echocardiographic parameters demonstrated enhanced cardiac function, with the left ventricular ejection fraction (LVEF) increasing from 43.89 ± 12.27% to 48.48 ± 10.57% (p < 0.05). The wall motion septal index (WMSI) decreased from 1.54 ± 0.18 to 1.24 ± 0.12, while global longitudinal strain (GLS) improved from -10.28 ± 2.82 to -12.74 ± 2.42. Myocardial perfusion imaging revealed marked reductions in summed stress score (SSS: 17.45 ± 8.61 vs 12.18 ± 7.89), summed rest score (SRS: 11.09 ± 7.74 vs 9.46 ± 7.23), and summed difference score (SDS: 4.37 ± 2.31 vs 2.57 ± 1.56; all p < 0.05). Severe perfusion defects decreased from 46.2% to 12.3% and extensive perfusion defect areas decreased from 60% to 26.2%. No adverse events, including arrhythmias or elevated cardiac enzyme levels, were reported.
Conclusion
Cardiac shock wave therapy is effective in patients with ischemic heart disease and refractory angina, as evidenced by improvements in clinical, functional, and imaging parameters, along with a favourable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Heart Institute, 108 Military Central Hospital, Hanoi, Vietnam.
- Department of Pathophysiology, Vietnam Military Medical University, Hanoi, Vietnam.
- Intensive Care Unit for Infectious Diseases, 108 Military Central Hospital, Hanoi, Vietnam.
ORCID-Profile: Pham Nguyen Son, Dinh Cong Pho
Zitieren
APA
Thanh, L. D., Bien, V. D., Son, P. N., Pho, D. C., Huy, P. X., Tuan, N. V., & Giang, P. T. (2025). The Effectiveness and Safety of Cardiac Shock Wave Therapy in the Treatment of Ischemic Heart Disease with Refractory Angina Pectoris. Vascular Health and Risk Management. https://doi.org/10.2147/vhrm.s559424
Vancouver
Thanh LD, Bien VD, Son PN, Pho DC, Huy PX, Tuan NV, et al. The Effectiveness and Safety of Cardiac Shock Wave Therapy in the Treatment of Ischemic Heart Disease with Refractory Angina Pectoris. Vascular Health and Risk Management. 2025. doi:10.2147/vhrm.s559424
BibTeX
@article{Thanh2025,
author = {Thanh, Le Duy and Bien, Vu Dien and Son, Pham Nguyen and Pho, Dinh Cong and Huy, Pham Xuan and Tuan, Nguyen Van and Giang, Pham Thai},
title = {The Effectiveness and Safety of Cardiac Shock Wave Therapy in the Treatment of Ischemic Heart Disease with Refractory Angina Pectoris},
journal = {Vascular Health and Risk Management},
year = {2025},
doi = {10.2147/vhrm.s559424}
}
EUVIMED